No Data
Q32 Bio Tanks 68% After Update On Its Eczema And Alopecia Treatment
Q32 Bio Shares Plunge On Data From Bempikibart Trials In Atopic Dermatitis And Alopecia Areata
Express News | Q32 Bio Shares Drop 67% After Co's Dermatitis Drug Fails in Part of a Study
Candel CADL Phase 3 Results; Q32 Bio QTTB Phase 2a Trial Fail
US Consumer Prices Rise in Line With Expectations in November as US Equity Futures Rise Pre-Bell
Express News | Q32 Bio Inc. : Oppenheimer Cuts Target Price to $20 From $80
AW138 : thank you sir, always appreciate your posts
DaTrader AW138 : I second that
WILLEE9ice : tons of thanks master, you have has done the jobs
Jenna Ragan : Thank you kindly
Tottigol10 : I can't understand unfortunately..any recommendations on where i can start to study and get more into it?
View more comments...